Article - 13/07/2015 CureVac and Boehringer Ingelheim - two strong partners forge cancer immunotherapy alliance Two German companies have teamed up to become a driving force in the immunotherapy of lung carcinomas. CureVac GmbH from Tübingen and Boehringer Ingelheim are working together on the development of a therapy for non-small cell lung cancer using CureVac’s vaccine CV9202. The drug is based on messenger RNA and will be used in combination with other therapies with the goal of fighting the tumour on several fronts.https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-and-boehringer-ingelheim-two-strong-partners-forge-cancer-immunotherapy-alliance
Article - 29/06/2015 How can influenza virus prediction be improved? Every February, the World Health Organisation (WHO) publishes recommendations on the composition of influenza virus vaccines for use in the upcoming influenza season. The WHO’s decision is based on observations and laboratory tests as well as experience and intuition. The particular type of influenza virus that is likely to be circulating in a given season has previously been mainly a matter of speculation. Richard Neher from the Max Planck…https://www.gesundheitsindustrie-bw.de/en/article/news/how-can-influenza-virus-prediction-be-improved
The Baden-Württemberg healthcare industry The pharmaceutical industry Baden-Württemberg is Germany’s largest pharma location. In addition to industry giants such as Roche, GlaxoSmithKline and Boehringer Ingelheim, Baden-Württemberg is home to a large number of small- and medium-sized pharmaceutical companies and biotech companies with pharmaceutical research and development.https://www.gesundheitsindustrie-bw.de/en/location/pharma
Dossier - 13/04/2015 Boosting the immune system can improve cancer prevention and treatment The activation of the body’s immune system to fight cancer is not only a promising therapeutic concept, but is already used in medical practice. The first immunotherapies have been approved and many more are either in the experimental stages or already undergoing clinical testing. Vaccines to prevent certain types of cancer are already being used successfully around the world.https://www.gesundheitsindustrie-bw.de/en/article/dossier/boosting-the-immune-system-can-improve-cancer-prevention-and-treatment
Article - 16/03/2015 Heike Brötz-Oesterhelt - searching for novel antibiotics in bacteria Microbial metabolic products can be used in the fight against dangerous pathogens such as multidrug-resistant bacteria. Since summer 2014, microbiologist Prof. Dr. Heike Brötz-Oesterhelt has been investigating the mechanisms of action of bacterial substances at the University of Tübingen with the aim of paving the way for new antibiotics. Interesting candidates have already been identified.https://www.gesundheitsindustrie-bw.de/en/article/news/heike-broetz-oesterhelt-searching-for-novel-antibiotics-in-bacteria
Article - 09/03/2015 Treating cancer by activating the immune system Vaccines that prevent infection with cancer-causing viruses are already available. Moreover, the development of therapeutic vaccines for the treatment of a number of other cancers is well under way. These vaccines not only prevent the development of cancer, but also treat early stages of cancer. Antigen-armed antibodies have long been used in vaccines against infectious diseases, and can now also be used for treating cancer. https://www.gesundheitsindustrie-bw.de/en/article/news/treating-cancer-by-activating-the-immune-system
Press release - 06/03/2015 The Bill & Melinda Gates Foundation invests €46 million in CureVac The Bill & Melinda Gates Foundation and CureVac announced that the foundation has made a commitment to invest €46 million in CureVac, a leading clinical-stage biopharmaceutical company specializing in mRNA-based vaccine technologies. As part of the agreement, the foundation will also provide separate funding for several projects to develop prophylactic vaccines based on CureVac’s proprietary messenger RNA platform. In addition, CureVac’s…https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-bill-melinda-gates-foundation-invests-46-million-in-curevac
Article - 16/02/2015 Therapeutic vaccines against brain tumours Therapeutic cancer vaccines have the potential to boost the immune system's ability to destroy tumour cells. Cancer researchers around the world are intensively studying the potential of this therapeutic concept and initial positive results have been obtained. Cancer researchers from Heidelberg have developed a vaccine that triggers an immune response against a protein that is mutated in brain cancer. The vaccine, which successfully arrested…https://www.gesundheitsindustrie-bw.de/en/article/news/therapeutic-vaccines-against-brain-tumours
Article - 26/01/2015 Pooling efforts against infectious diseases in Germany Over 150 scientists at various locations throughout Germany work together as part of the German Centre for Infection Research (DZIF). The centre focuses on the development of new diagnostic, preventive and therapeutic methods for treating infectious diseases. Scientists from the University and University Hospital of Tübingen and the Max Planck Institute for Developmental Biology are also part of the project. The researchers from Tübingen are…https://www.gesundheitsindustrie-bw.de/en/article/news/pooling-efforts-against-infectious-diseases-in-germany
Article - 22/12/2014 Fighting hepatitis viruses with their own weapons Virologist Prof. Dr. Stephan Urban from the University of Heidelberg has been awarded the DZIF Prize for Translational Infection Research for the discovery and development of a promising peptide drug for the treatment of hepatitis B virus infections. The peptide prevents viruses from entering the liver cells, and is also effective against hepatitis D infection. Hepatitis D is the deadliest of all viral liver diseases and no specific antiviral…https://www.gesundheitsindustrie-bw.de/en/article/news/fighting-hepatitis-viruses-with-their-own-weapons
Article - 20/10/2014 Michael Schindler: HI virus and host interactions Prof. Dr. Michael Schindler explores the interaction between viruses and their human host cells on the molecular level. His specific interest is HI virus infections and the mechanisms the virus uses to attack the human immune system. Schindler’s eventual aim is to identify a new target for the therapy of HIV infections. In April 2014, Schindler was appointed head of the Department of Molecular Virology of Human Infectious Diseases at the…https://www.gesundheitsindustrie-bw.de/en/article/news/michael-schindler-hi-virus-and-host-interactions
Article - 18/08/2014 VAXIMM: Vaccines that impede cancer growth VAXIMM GmbH, a young biotechnology company from Mannheim, Germany, specialises in the development of vaccines for cancer treatment. The company’s first product candidate, VXM01, is a live oral vaccine that targets the VEGFR-2 receptor and hence the blood supply of tumours. VXM01 is currently undergoing clinical testing in pancreatic cancer patients.https://www.gesundheitsindustrie-bw.de/en/article/news/vaximm-vaccines-that-impede-cancer-growth
Dossier - 31/03/2014 Peptides – diverse molecules of life Peptides exist in all organisms, wherever there are cells. The range of their physiological functions is huge. Biologically active peptides can act as hormones, neurotransmitters, growth factors as well as toxins and antibiotics. This is what makes them highly interesting drug leads. They are used for the treatment of autoimmune diseases, cancer and other diseases. Despite some drawbacks, peptides are gaining in importance as candidates for drugs…https://www.gesundheitsindustrie-bw.de/en/article/dossier/peptides-diverse-molecules-of-life
Article - 24/03/2014 Vaccine against papillomaviruses protects from skin cancer Papillomaviruses are thought to cause non-melanoma skin cancer in people exposed to UV radiation, especially those who have suppressed immune systems. Researchers from the German Cancer Research Center (DKFZ) and the Charité University Hospital in Berlin have developed a vaccine that protects mice against such skin tumours. The vaccine is even effective in mice that have previously been infected with papillomaviruses and that have suppressed…https://www.gesundheitsindustrie-bw.de/en/article/news/vaccine-against-papillomaviruses-protects-from-skin-cancer
Press release - 11/03/2014 CureVac Wins Two Million EUR from Inaugural European Commission Vaccine Prize 10 March 2014 CureVac a German clinical stage biopharmaceutical company today announced that it has won the inaugural European Commission Vaccine Prize. The EU has dedicated the prize of two million Euros in an effort to stimulate innovative solutions for vaccine transportation and storage where cold chain cannot be guaranteed. CureVacs RNActive vaccine technology based on messenger RNA mRNA convinced the panel of judges of its potential as a…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-wins-two-million-eur-from-inaugural-european-commission-vaccine-prize
Article - 27/01/2014 immatics biotechnologies GmbH: active against cancer immatics biotechnologies GmbH is a biopharmaceutical company wholly concerned with the development of advanced immunotherapies that are active against different types of cancer, including renal cell, colorectal, brain and gastric cancer. The company currently has a workforce of 80 at its headquarters in Tübingen and subsidiary in Munich. It capitalises on the know-how in the analysis of tumour cells and vaccine development gained through its…https://www.gesundheitsindustrie-bw.de/en/article/news/immatics-biotechnologies-gmbh-active-against-cancer
Article - 20/01/2014 Microarray copier – for copying DNA, RNA and protein arrays Dr. Günter Roth from the Centre for Biological Systems Analysis at the University of Freiburg is working on the development of a microarray copier that can almost at the push of a button copy arrays of any type of molecule DNA RNA and proteins from next-generation sequencing chips onto standard slides thereby combining the world of microarrays with the sequencing world. The approach has a huge application potential for the production of…https://www.gesundheitsindustrie-bw.de/en/article/news/microarray-copier-for-copying-dna-rna-and-protein-arrays
Press release - 15/10/2013 Biotech financing in Baden-Württemberg: immatics raises 34 million Euros The immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer, today announced that it has closed a 34 million Euros Series D financing round. The funding round was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, MIG-advised funds and AT Impf GmbH. Under the terms of the fundraising, immatics will receive…https://www.gesundheitsindustrie-bw.de/en/article/press-release/biotech-financing-in-baden-wuerttemberg-immatics-raises-34-million-euros
Article - 30/09/2013 CureVac GmbH: RNA-based vaccines and immunotherapies CureVac GmbH, a biopharmaceutical company based in Tübingen, develops immunotherapies for cancer along with prophylactic vaccines based on its proprietary messenger RNA (mRNA) technology platform. CureVac also uses RNA for developing adjuvants. Two clinical trials, a Phase I trial in non-small cell lung cancer (NSCLC) and a Phase IIb trial in prostate cancer, are currently underway to test the efficiency of mRNA-based drugs in treating cancer and…https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-gmbh-rna-based-vaccines-and-immunotherapies
Article - 08/07/2013 Christine Goffinet: independent and successful AIDS researchers Christine Goffinet, 36, from the Institute of Molecular Virology at the University of Ulm has already received numerous awards for her research on AIDS. She was recently awarded a scholarship for postdoctoral lecture qualification under the Margarete von Wrangell Habilitation Programme. However, before she became a virologist, Goffinet chose a career path that was quite different from the standard career path seen on many scientific CVs.https://www.gesundheitsindustrie-bw.de/en/article/news/christine-goffinet-independent-and-successful-aids-researchers
Article - 17/05/2013 Dengue fever, the neglected infectious disease Dengue fever is the most common infectious disease transmitted by mosquitoes. The disease is spreading in Europe and Germany, an upward trend that is due to increased long-distance travel. There are no specific drugs or vaccine for dengue, which is why an international research network has been established to improve the management of the disease. The consortium is coordinated by the Department of Tropical Medicine at Heidelberg University.https://www.gesundheitsindustrie-bw.de/en/article/news/dengue-fever-the-neglected-infectious-disease
Press release - 30/04/2013 Impressions from the 2013 BIO International Convention in Chicago A trade fair turns 20 and an industrial sector is coming of age. Where does BIO stand today? The number of exhibitors has slightly decreased the conference is characterised by general themes and trends and partnering has become the most important and indispensable part of the global event for biotechnology. What was once a gold rush atmosphere has given way to an experienced self-confidence about the economic importance of biotechnology. https://www.gesundheitsindustrie-bw.de/en/article/press-release/impressions-from-the-2013-bio-international-convention-in-chicago
Dossier - 01/04/2013 Retroviruses: from infectious agent to therapeutic assistant Viruses are infectious particles that use the machinery and metabolism of a host cell to replicate. Despite some similarities with accepted forms of life viruses are not considered as such. The family of retroviruses is particularly known for its most notorious representative i. e. the human immunodeficiency virus HIV which leads to AIDS and for which no cure or effective vaccine is currently available. However retroviruses are not only of…https://www.gesundheitsindustrie-bw.de/en/article/dossier/retroviruses-from-infectious-agent-to-therapeutic-assistant
Article - 04/02/2013 G protein-coupled receptors and their importance for research and development Brian Kobilka and Robert Lefkowitz were awarded the 2012 Nobel Prize in Chemistry for their groundbreaking discoveries of the inner workings of G protein-coupled receptors (GPCRs). These transmembrane receptors play a key role in the processing of odours and the recognition of hormones. The work of the two American scientists has had an impact on many researchers around the world. In the following interview, Professor Dr. Daniel Legler, head of…https://www.gesundheitsindustrie-bw.de/en/article/news/g-protein-coupled-receptors-and-their-importance-for-research-and-development
Press release - 13/11/2012 immatics’ renal cancer vaccine IMA901 completes phase 3 patient recruitment immatics biotechnologies GmbH announced that it has completed patient recruitment into the pivotal phase 3 trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma RCC. The first interim overall survival results are expected during the first half of 2014.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-renal-cancer-vaccine-ima901-completes-phase-3-patient-recruitment
Press release - 12/11/2012 immatics appoints Peter Chambré as Chairman immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced the appointment of Peter Chambré as Chairman of the Board with immediate effect. Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry. He will replace Thomas Widmann, who has…https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-peter-chambr-as-chairman
Press release - 30/10/2012 DKFZ and Genetic Immunity Sign Collaboration Agreement to Develop HPV Therapeutic Vaccine Genetic Immunity, Budapest, a leader in immunotherapy technology product development, and DKFZ (German Cancer Research Center, Heidelberg, Germany) signed a collaborative agreement to develop a DNA-based vaccine for the treatment of Human Papilloma Virus (HPV) infection that causes cervical cancer and other cancers of the anus, penis, vulva, vagina, and oropharynx. Present HPV vaccines (Cervarix, Gardasil) have no therapeutic effect on…https://www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-and-genetic-immunity-sign-collaboration-agreement-to-develop-hpv-therapeutic-vaccine
Article - 15/10/2012 gerbion®: hunting down pathogens Detecting viruses, bacteria or parasites in human, animal, food and environmental samples is routine for the staff of gerbion GmbH & Co. KG. The company has been using virological, microbiological and serological methods for many years, but is now also using cutting-edge molecular biology methods for detecting pathogens. The founders of the Kornwestheim-based diagnostics company have concentrated on own research work and the development of…https://www.gesundheitsindustrie-bw.de/en/article/news/gerbion-hunting-down-pathogens
Press release - 18/09/2012 CureVac Secures €80 Million in Series D Financing CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, announced on september 18 the completion of an €80 million financing round with its main investor, dievini Hopp BioTech Holding. In the next years, CureVac will use the proceeds mainly to advance the development of its two lead RNActive® cancer vaccines against prostate cancer and non-small cell lung cancer (NSCLC),…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-secures-80-million-in-series-d-financing
Article - 03/09/2012 Systems biology and hepatitis C research The international research project SysPatho aims to advance the understanding of HCV (hepatitis C virus) infections using systems biology approaches. The goal of the project coordinated by Universität Heidelberg is to develop new mathematical and computational methods to reconstruct HCV-infected hepatocytes, which can be used to identify new drug targets and help treat this dangerous disease.https://www.gesundheitsindustrie-bw.de/en/article/news/systems-biology-and-hepatitis-c-research
Press release - 07/08/2012 immatics announces publication of IMA901 cancer vaccine data in Nature Medicine immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine, IMA901, have been published in Nature Medicine. The paper highlights that renal cell carcinoma patients experience longer survival times when their immune system produces an immune response to…https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-announces-publication-of-ima901-cancer-vaccine-data-in-nature-medicine
Article - 16/07/2012 Laupheim to become an international forum for biomanufacturing The 2nd Laupheimer Zelltage conference organized by Rentschler Biotechnologie GmbH in Laupheim on 11th and 12th June 2012 focused on “Bioprocess light”. Twelve experts from applied research institutions and biotech companies from Germany and abroad provided the 200 or so guests with information on how modern bioproduction methods can be made simpler, more robust, cheaper, more reliable and hence more competitive.https://www.gesundheitsindustrie-bw.de/en/article/news/laupheim-to-become-an-international-forum-for-biomanufacturing
Press release - 01/06/2012 immatics wins 2012 TiE50 Award Immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that it has been named a 2012 TiE50 winner. These prestigious awards recognize entrepreneurship, innovation and management excellence within the life sciences, software, internet, mobile and energy sectors.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-wins-2012-tie50-award
Dossier - 30/04/2012 Human infectious diseases: new threats The serious EHEC outbreak in Germany in 2011, the 2009 swine flu pandemic, the bird flu pandemic in 2005 and 2006 and the SARS outbreak in China in 2003, all of which have fuelled the fear of devastating epidemics for many people in Germany, have fortunately all been contained – at least up until now. However, experts warn of new dangerous pathogens that are spreading as a result of globalization and global climate warming. This is leading to new…https://www.gesundheitsindustrie-bw.de/en/article/dossier/human-infectious-diseases-new-threats
Press release - 18/04/2012 immatics appoints Dr. Rainer Kramer as Chief Business Officer immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing therapeutic vaccines that are active against cancer, today announced the appointment of Dr. Rainer Kramer as Chief Business Officer (CBO) with immediate effect. In this newly created role, Dr. Kramer will lead immatics’ Business Development Unit in order to create optimal value from the Company’s pipeline of therapeutic cancer vaccines.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-dr-rainer-kramer-as-chief-business-officer
Article - 20/02/2012 Microporation: an innovative laser replaces jabs People who are afraid of needles now have something to celebrate: hypodermic needles, which have long been the key instrument for administering drugs used to treat allergies and diseases as well as for vaccinations, now have a serious competitor. The minimally invasive P.L.E.A.S.E. ® platform developed by Pantec Biosolutions AG combines a laser device and stick-on patches to deliver drugs transdermally and painlessly into the bloodstream. The…https://www.gesundheitsindustrie-bw.de/en/article/news/microporation-an-innovative-laser-replaces-jabs
Press release - 02/02/2012 Colorectal cancer: Phase II results with cancer vaccine IMA910 are positive immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced positive results from its Phase II clinical trial with IMA910 in patients with advanced colorectal cell carcinoma (CRC) which were presented at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in San Francisco. IMA910 comprises 13 tumor-associated…https://www.gesundheitsindustrie-bw.de/en/article/press-release/colorectal-cancer-phase-ii-results-with-cancer-vaccine-ima910-are-positive
Article - 19/12/2011 Gundram Jung – a pioneer in antibody-mediated cancer immunotherapy Physicist, medical doctor, researcher and now also a founder of a company – Professor Dr. Gundram Jung’s career has never gone in a completely straight line although his goal has always been the same: to develop innovative immunotherapies for the treatment of cancer. Jung’s genetically modified antitumour antibodies are now close to clinical application. https://www.gesundheitsindustrie-bw.de/en/article/news/gundram-jung-a-pioneer-in-antibody-mediated-cancer-immunotherapy
Article - 21/11/2011 Johannes Huebner's interest in intestinal bacteria and their sweet-sour capsule Some Enterococcus species are common commensal organisms in human intestines and other species are used in raw-milk cheese where they enhance flavour development. On the negative side enterococci are also a common cause of hospital-acquired infections. Prof. Dr. Johannes Huebner from the Freiburg University Medical Centre is hoping that the bacterias capsular polysaccharides might at some point in the future be used as a vaccine opening the door…https://www.gesundheitsindustrie-bw.de/en/article/news/johannes-huebner-s-interest-in-intestinal-bacteria-and-their-sweet-sour-capsule
Press release - 15/11/2011 Lung cancer: CureVac presents results of a Phase I/IIa trial with an mRNA based vaccine CureVac GmbH, the mRNA vaccine company, presented at the 26th Annual SITC Meeting in Washington the results of a Phase I/IIa trial in non-small cell lung cancer (NSCLC) with CV9201, an mRNA-based cancer vaccine, in patients with NSCLC stage IIIB/IV after first-line chemo-radiotherapy or chemotherapy, respectively.https://www.gesundheitsindustrie-bw.de/en/article/press-release/lung-cancer-curevac-presents-results-of-a-phase-i-iia-trial-with-an-mrna-based-vaccine
Press release - 15/11/2011 CureVac, Sanofi Pasteur and In-Cell-Art collaborate on a $33.1 million project CureVac GmbH today announced the signing of several agreements with Sanofi Pasteur S.A., the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY). Under these agreements, CureVac and Sanofi Pasteur will further develop and apply CureVac’s proprietary RNActive® technology platform to the development of vaccines against several infectious diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-sanofi-pasteur-and-in-cell-art-collaborate-on-a-33-1-million-project
Article - 17/10/2011 Papillomaviruses as cancer-causing agents and how they can be fought off Studies presented at the recent International Papillomavirus Conference in Berlin demonstrate that vaccination can prevent infection with the types of HPV that cause the majority of cervical cancers. New improved vaccines to prevent HPV infections as well as therapeutic vaccines that are effective in people that are already infected are currently being developed. In addition, research has shown that other cancers can also be caused by infective…https://www.gesundheitsindustrie-bw.de/en/article/news/papillomaviruses-as-cancer-causing-agents-and-how-they-can-be-fought-off
Article - 12/09/2011 TransLimm brings new immunotherapies to patients more rapidly With the establishment of the Center for Translational Immunology TransLimm the University of Tübingen has initiated a network whose objective is to quickly and effectively transfer innovative therapies into clinical application. Patients suffering from acute leukaemia might soon benefit from therapies involving antibodies optimized by recombinant antibody technology. https://www.gesundheitsindustrie-bw.de/en/article/news/translimm-brings-new-immunotherapies-to-patients-more-rapidly
Article - 29/07/2011 Labor Dr. Merk und Kollegen - Viruses under control It is difficult to imagine how Ochsenhausen-based Labor Dr. Merk und Kollegen (LMK) would be able to develop, produce and test medical products for bacterial and viral contaminations without using cell cultures. The medium-sized company also produces viruses for testing and has stored more than 80 different viruses – enveloped and non-enveloped ones, animal and human pathogens – at -80˚C.https://www.gesundheitsindustrie-bw.de/en/article/news/labor-dr-merk-und-kollegen-viruses-under-control
Press release - 20/06/2011 CureVac presents new data for prostate and lung cancer vaccines CureVac GmbH presented promising new data for prostate cancer vaccine CV9103 and lung cancer vaccine CV9201 at the ASCO Conference in Chicago. Final trial results confirm safety and excellent antigen-specific immunogenicity of prostate cancer vaccine CV9103. And initial promising data from phase I/IIa trial of lung cancer vaccine CV9201 further supports the potential of CureVac’s RNActive® vaccination technology in cancer immunotherapy and…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-presents-new-data-for-prostate-and-lung-cancer-vaccines
Press release - 15/06/2011 immatics’ pivotal Phase III trial with IMA901: First patients with renal cell carcinoma are vaccinated immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company’s lead cancer vaccine for the treatment of renal cell carcinoma (RCC).https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-pivotal-phase-iii-trial-with-ima901-first-patients-with-renal-cell-carcinoma-are-vaccinated
Press release - 02/03/2011 immatics appoints Dr. Harald Stock to its Board immatics biotechnologies GmbH, a late-stage biopharmaceutical company developing therapeutic vaccines that are active against cancer, today announced the appointment of Dr. Harald F. Stock to the board of directors, effective February 2011.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-dr-harald-stock-to-its-board
Dossier - 28/02/2011 Allergies – a major human plague According to the Federal Health Monitoring Information System a persons life expectancy is reduced by around one per cent due to allergies and their effects. Knowledge about the molecular mechanisms that lead to disorders in the interplay of the immune system and the environment is a prerequisite for developing new therapies for the causal treatment of allergies.https://www.gesundheitsindustrie-bw.de/en/article/dossier/allergies-a-major-human-plague
Article - 28/02/2011 Development of food allergies Allergic reactions to certain types of food can, in extreme cases, lead to life-threatening anaphylactic shock. People with peanut allergies are particularly at risk. Allergic reactions can also gradually develop into chronic intolerances such as coeliac disease, for example. The causes of food allergies nearly always originate in early childhood. https://www.gesundheitsindustrie-bw.de/en/article/news/development-of-food-allergies
Article - 14/02/2011 Marilena Manea: targeted chemotherapy to treat cancer After cardiovascular diseases cancer is the second leading cause of death in Germany. At the University of Konstanz Dr. Marilena Manea and her research group are working on the development of bioconjugates for targeted cancer chemotherapy. The researchers goal is to improve the efficiency and tolerability of the chemotherapeutic drugs that are already being used in hospitals.https://www.gesundheitsindustrie-bw.de/en/article/news/marilena-manea-targeted-chemotherapy-to-treat-cancer